ANN.AX · ASX · Healthcare
Ansell Limited
Also onShortfallConsensus DriftCrosscheck
Implied value per share
AUD 10.97
Market price
AUD 42.31
Implied upside
-74.1%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case · USD model at 1.4042
Current EV/EBITDA of 20.2x sits outside a defensible 3-20x band, so the exit multiple is capped at 20.0x. A multiple that far out usually means EBITDA is the wrong denominator for this business.
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY27 | FY28 | FY29 | FY30 | FY31 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 2.3bn | USD 2.5bn | USD 2.8bn | USD 3.0bn | USD 3.3bn | +8.9% |
| EBIT | USD 167.0m | USD 181.9m | USD 198.2m | USD 215.9m | USD 235.2m | +8.9% |
| NOPAT | USD 122.7m | USD 133.7m | USD 145.6m | USD 158.7m | USD 172.8m | +8.9% |
| Add depreciation & amortisation | USD 93.6m | USD 101.9m | USD 111.0m | USD 121.0m | USD 131.8m | +8.9% |
| Less capital expenditure | USD -79.8m | USD -86.9m | USD -94.7m | USD -103.2m | USD -112.4m | +8.9% |
| Less increase in working capital | USD -71.4m | USD -77.8m | USD -84.8m | USD -92.4m | USD -100.7m | +8.9% |
| Free cashflow to firm | USD 65.0m | USD 70.8m | USD 77.2m | USD 84.1m | USD 91.6m | +8.9% |
| Discount factor | 0.9575 | 0.8778 | 0.8047 | 0.7378 | 0.6764 | - |
| Present value | USD 62.3m | USD 62.2m | USD 62.1m | USD 62.0m | USD 62.0m | -0.1% |
| Present Value Of The Forecast | USD 310.5m | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 5.35% | Australian Government 10-year (RBA F2) |
| Equity risk premium | 6.00% | Market assumption |
| Beta | 0.731 | Reported 0.598, pulled toward 1.0 (Blume) |
| Cost of equity | 9.73% | Risk-free + beta x equity risk premium |
| Cost of debt | 5.35% | Floored at the risk-free rate (implied cost of debt was lower) |
| Market capitalisation | USD 6.0bn | 88.7% of capital |
| Total debt | USD 756.6m | 11.3% of capital, book value as a proxy |
| Tax rate | 26.5% | Effective, capped at statutory |
| WACC | 9.08% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
81% of EV
- Forecast FCFF, final year
- USD 91.6m
- Capex at depreciation, working capital in reinvestment
- USD 172.8m
- Less reinvestment at g/ROIC (27.5% of NOPAT)
- USD -47.6m
- Capitalised
- USD 125.2m
- ROIC (WACC floor)
- 9.1%
- Terminal value, undiscounted
- USD 2.0bn
- Terminal value, discounted
- USD 1.3bn
- Enterprise value
- USD 1.6bn
- Less net debt
- USD 507.1m
- Equity value
- USD 1.1bn
Exit at 20.0x EBITDA
94% of EV
- Terminal value, undiscounted
- USD 7.3bn
- Terminal value, discounted
- USD 5.0bn
- Enterprise value
- USD 5.3bn
- Less net debt
- USD 507.1m
- Equity value
- USD 4.8bn
Spread between methods: 124%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 7.08% | 11.41 | 11.47 | 11.53 | 11.60 | 11.66 |
| 8.08% | 9.33 | 9.39 | 9.44 | 9.49 | 9.54 |
| 9.08% | 7.73 | 7.77 | 7.81 | 7.86 | 7.90 |
| 10.08% | 6.44 | 6.48 | 6.52 | 6.56 | 6.60 |
| 11.08% | 5.40 | 5.44 | 5.47 | 5.50 | 5.54 |
Outlined: this model. Green text: above today's price of 30.13. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 8.9% | 53.5% | +44.6pp |
| EBIT margin | 7.2% | 19.2% | +12.1pp |
| Discount rate | 9.1% | 3.8% | -5.3pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.